DaTscan: Phase IV data

An open-label, international Phase IV trial in 273 patients with clinically uncertain Parkinsonian syndrome showed that a significantly greater proportion of patients who underwent DaTscan imaging reported changes in diagnosis compared to the no imaging control group at 4 weeks (45% vs. 9%, p<0.001), 12 weeks (46% vs. 12%, p<0.001) and 1 year (54% vs. 23%, p<0.001). Additionally, a significantly greater proportion of patients who underwent DaTscan imaging had changes in their clinical management compared to the control group at 12 weeks (50% vs. 31%, p=0.002) and at 1 year (41% vs. 22%, p<0.001). Furthermore, a significantly greater mean change from baseline in physician confidence of diagnosis was observed in patients who underwent DaTscan imaging vs. the control group at all time points (p<0.001 for all). Data were presented at the Movement Disorders Society meeting in Dublin. ...